Artivion, Inc. (NYSE:AORT) Shares Bought by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC boosted its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 40.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 306,702 shares of the company's stock after buying an additional 88,902 shares during the quarter. Lord Abbett & CO. LLC owned approximately 0.73% of Artivion worth $8,769,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares in the last quarter. R Squared Ltd purchased a new position in Artivion in the 4th quarter valued at about $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion during the 4th quarter worth about $43,000. Venturi Wealth Management LLC purchased a new stake in shares of Artivion during the fourth quarter worth about $78,000. Finally, GAMMA Investing LLC raised its position in shares of Artivion by 21.8% in the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company's stock valued at $79,000 after buying an additional 497 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Insider Activity at Artivion

In other Artivion news, SVP Jean F. Holloway sold 18,020 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $425,452.20. Following the transaction, the senior vice president now owns 197,184 shares in the company, valued at $4,655,514.24. The trade was a 8.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John E. Davis sold 15,100 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the completion of the sale, the insider now owns 208,778 shares of the company's stock, valued at approximately $4,929,248.58. This trade represents a 6.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,799 shares of company stock worth $2,356,223. Company insiders own 7.60% of the company's stock.

Artivion Trading Up 0.1 %

Shares of AORT traded up $0.03 during mid-day trading on Friday, reaching $23.36. The company had a trading volume of 253,995 shares, compared to its average volume of 302,567. Artivion, Inc. has a fifty-two week low of $20.98 and a fifty-two week high of $32.33. The firm has a fifty day simple moving average of $23.95 and a 200-day simple moving average of $27.20. The stock has a market cap of $997.22 million, a price-to-earnings ratio of -1,168.00 and a beta of 1.65. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analysts' expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Ratings Changes

AORT has been the subject of several recent analyst reports. Stifel Nicolaus lowered their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Needham & Company LLC lowered their price objective on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.